Novo Nordisk’s stock is rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long
marketwatch.com/story/novo-nordisks-stock-is-rallying-as-hims-hers-stock-falters-an-ozempic-alternative-wont-be-available-for-long-464065f1Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.
This story appeared on marketwatch.com, 2025-02-25 12:29:00.